Susan Goodin

Summary

Affiliation: New Jersey
Country: USA

Publications

  1. doi request reprint Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer
    Susan Goodin
    Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, USA
    Am J Health Syst Pharm 65:2017-26. 2008
  2. ncbi request reprint Erlotinib: optimizing therapy with predictors of response?
    Susan Goodin
    Pharmaceutical Sciences, The Cancer Institute of New Jersey and Division of Medical Oncology, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, NJ 08903 2681, USA
    Clin Cancer Res 12:2961-3. 2006
  3. ncbi request reprint Selecting an anticoagulant for recurrent venous thromboembolism in cancer
    Susan Goodin
    Division of Pharmaceutical Sciences, The Cancer Institute of New Jersey, USA
    Am J Health Syst Pharm 62:S10-3. 2005
  4. ncbi request reprint Clinical and biological activity of soy protein powder supplementation in healthy male volunteers
    Susan Goodin
    Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, NJ 08903 2681, USA
    Cancer Epidemiol Biomarkers Prev 16:829-33. 2007
  5. ncbi request reprint Oral chemotherapeutic agents: understanding mechanisms of action and drug interactions
    Susan Goodin
    University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, NJ 08901, USA
    Am J Health Syst Pharm 64:S15-24. 2007
  6. ncbi request reprint Current issues associated with oral chemotherapy: a roundtable discussion
    Susan Goodin
    Medical Oncology, The Cancer Institute of New Jersey, 195 Little Albany Street, Room 2012, New Brunswick, NJ 08903 2681, USA
    Am J Health Syst Pharm 64:S33-5. 2007
  7. ncbi request reprint NSAIDs for the chemoprevention of oral cancer: promise or pessimism?: Commentary re J. L. Mulshine et al., randomized, double-blind, placebo-controlled, phase IIB trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplaki
    Susan Goodin
    Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903, USA
    Clin Cancer Res 10:1561-4. 2004
  8. doi request reprint Novel cytotoxic agents: epothilones
    Susan Goodin
    The Cancer Institute of New Jersey, New Brunswick, New Jersey, USA
    Am J Health Syst Pharm 65:S10-5. 2008
  9. doi request reprint Progress in the development of monoclonal antibody therapies for colorectal cancer. Introduction
    Susan Goodin
    Division of Pharmaceutical Sciences, The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, 195 Little AlbanyStreet, New Brunswick, NJ 08901, USA
    Am J Health Syst Pharm 65:S2. 2008
  10. doi request reprint Development of monoclonal antibodies for the treatment of colorectal cancer
    Susan Goodin
    Division of Pharmaceutical Sciences, The Cancer Institute of New Jersey, and University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, 195 Little AlbanyStreet, New Brunswick, NJ 08901, USA
    Am J Health Syst Pharm 65:S3-7; quiz S22-4. 2008

Collaborators

Detail Information

Publications40

  1. doi request reprint Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer
    Susan Goodin
    Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, USA
    Am J Health Syst Pharm 65:2017-26. 2008
    ..The pharmacology, pharmacokinetics, clinical efficacy, safety, dosage, and administration of ixabepilone in patients with metastatic breast cancer are examined...
  2. ncbi request reprint Erlotinib: optimizing therapy with predictors of response?
    Susan Goodin
    Pharmaceutical Sciences, The Cancer Institute of New Jersey and Division of Medical Oncology, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, NJ 08903 2681, USA
    Clin Cancer Res 12:2961-3. 2006
  3. ncbi request reprint Selecting an anticoagulant for recurrent venous thromboembolism in cancer
    Susan Goodin
    Division of Pharmaceutical Sciences, The Cancer Institute of New Jersey, USA
    Am J Health Syst Pharm 62:S10-3. 2005
    ....
  4. ncbi request reprint Clinical and biological activity of soy protein powder supplementation in healthy male volunteers
    Susan Goodin
    Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, NJ 08903 2681, USA
    Cancer Epidemiol Biomarkers Prev 16:829-33. 2007
    ....
  5. ncbi request reprint Oral chemotherapeutic agents: understanding mechanisms of action and drug interactions
    Susan Goodin
    University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, NJ 08901, USA
    Am J Health Syst Pharm 64:S15-24. 2007
    ..The mechanisms of action and drug interactions of oral chemotherapeutic agents are reviewed...
  6. ncbi request reprint Current issues associated with oral chemotherapy: a roundtable discussion
    Susan Goodin
    Medical Oncology, The Cancer Institute of New Jersey, 195 Little Albany Street, Room 2012, New Brunswick, NJ 08903 2681, USA
    Am J Health Syst Pharm 64:S33-5. 2007
  7. ncbi request reprint NSAIDs for the chemoprevention of oral cancer: promise or pessimism?: Commentary re J. L. Mulshine et al., randomized, double-blind, placebo-controlled, phase IIB trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplaki
    Susan Goodin
    Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903, USA
    Clin Cancer Res 10:1561-4. 2004
  8. doi request reprint Novel cytotoxic agents: epothilones
    Susan Goodin
    The Cancer Institute of New Jersey, New Brunswick, New Jersey, USA
    Am J Health Syst Pharm 65:S10-5. 2008
    ..The epothilones are effective antitumor medications for patients with breast cancer, including patients who have been previously treated with or are resistant to anthracyclines or the taxanes...
  9. doi request reprint Progress in the development of monoclonal antibody therapies for colorectal cancer. Introduction
    Susan Goodin
    Division of Pharmaceutical Sciences, The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, 195 Little AlbanyStreet, New Brunswick, NJ 08901, USA
    Am J Health Syst Pharm 65:S2. 2008
  10. doi request reprint Development of monoclonal antibodies for the treatment of colorectal cancer
    Susan Goodin
    Division of Pharmaceutical Sciences, The Cancer Institute of New Jersey, and University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, 195 Little AlbanyStreet, New Brunswick, NJ 08901, USA
    Am J Health Syst Pharm 65:S3-7; quiz S22-4. 2008
    ....
  11. ncbi request reprint 5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile
    Susan Goodin
    The Cancer Institute of New Jersey, New Brunswick 08903, USA
    Oncologist 7:424-36. 2002
    ..Clinicians are encouraged to evaluate patients on an individual basis when choosing which 5-HT(3)-receptor antagonist to prescribe...
  12. ncbi request reprint A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer
    Susan Goodin
    Department of Medicine, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA
    Cancer Chemother Pharmacol 56:199-204. 2005
    ..The combination of docetaxel and vinorelbine with filgrastim was well tolerated and active against HRPC in patients with or without prior chemotherapy...
  13. ncbi request reprint Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer
    Susan Goodin
    Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, Piscataway, USA
    J Clin Oncol 23:3352-7. 2005
    ..To evaluate docetaxel in the treatment of patients with early-stage prostate cancer with prostate-specific antigen (PSA) progression after local therapy without androgen ablation therapy...
  14. pmc Transdermal estradiol in castrate and chemotherapy resistant prostate cancer
    Mark Stein
    The Cancer Institute of New Jersey, UMDNJ RWJMS, New Brunswick, NJ 08901, USA
    Med Sci Monit 18:CR260-4. 2012
    ....
  15. doi request reprint Ixabepilone, a new treatment option for metastatic breast cancer
    Deborah L Toppmeyer
    Department of Medicine, Cancer Institute of New Jersey, New Brunswick, 08901 USA
    Am J Clin Oncol 33:516-21. 2010
    ..Further clinical studies are evaluating the combination of ixabepilone with targeted agents such as trastuzumab or bevacizumab to further define the role of this novel agent in the treatment of MBC...
  16. ncbi request reprint Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival
    Jennifer Nishioka
    The Cancer Institute of New Jersey, UMDNJ Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, New Jersey 08901, US
    J Oncol Pharm Pract 13:85-97. 2007
    ....
  17. ncbi request reprint A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer
    Kamakshi Rao
    The Dean and Betty Gallo Prostate Cancer Center at The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, USA
    Prostate 62:115-22. 2005
    ....
  18. ncbi request reprint Epothilones: mechanism of action and biologic activity
    Susan Goodin
    Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, USA
    J Clin Oncol 22:2015-25. 2004
    ..The results suggest that these compounds have a broad range of antitumor activity at doses and schedules associated with tolerable side effects...
  19. ncbi request reprint Tubulin-targeting agents
    William N Hait
    UMDNJ Robert Wood Johnson Medical School, Department of Medicine, New Brunswick, NJ 08901 1914, USA
    Cancer Chemother Biol Response Modif 21:41-67. 2003
  20. ncbi request reprint Antiemetic care for patients with breast cancer: focus on drug interactions and safety concerns
    Angela Georgy
    Pharmaceutical Industry Fellowship Institute, School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA
    Am J Health Syst Pharm 64:2227-36. 2007
    ..The drug interactions and adverse events that should be considered when individualizing antiemetic therapy for patients undergoing treatment for breast cancer are reviewed...
  21. doi request reprint Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies
    Mark Stein
    Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey 08901, USA
    Prostate 70:1388-94. 2010
    ....
  22. doi request reprint A validated bioanalytical HPLC method for pharmacokinetic evaluation of 2-deoxyglucose in human plasma
    Murugesan K Gounder
    The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, USA
    Biomed Chromatogr 26:650-4. 2012
    ..8 to 110.0%. The HPLC method is reproducible and suitable for the quantitation of 2-DG in plasma. The method was successfully applied to characterize the pharmacokinetics profile of 2-DG in patients with advanced solid tumors...
  23. ncbi request reprint Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors
    Antoinette R Tan
    The Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA
    Clin Cancer Res 12:6517-22. 2006
    ..The purpose of this trial was to evaluate the pharmacokinetics of cetuximab given as a single dose followed by weekly fixed repeated dosing in patients with solid tumors...
  24. ncbi request reprint Tubulin-targeting agents
    William N Hait
    UMDNJ Robert Wood Johnson Medical School, Department of Medicine, The Cancer Institute of New Jersey, New Brunswick 08901 1914, USA
    Cancer Chemother Biol Response Modif 22:35-59. 2005
  25. doi request reprint Management of venous thromboembolism and the potential to impact overall survival in patients with cancer
    Biren Saraiya
    Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, USA
    Pharmacotherapy 29:1344-56. 2009
    ..Aggressive VTE management and strategies are critical to improving survival in patients with cancer and VTE...
  26. doi request reprint Overcoming drug resistance in patients with metastatic breast cancer
    Serena T Wong
    Department of Medicine, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey 08903, USA
    Pharmacotherapy 29:954-65. 2009
    ....
  27. doi request reprint Full costs of dispensing and administering fluorouracil chemotherapy for outpatients: A microcosting study
    Dong Churl Suh
    Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854 8020, USA
    Res Social Adm Pharm 6:246-56. 2010
    ....
  28. ncbi request reprint Tubulin-targeting agents
    William N Hait
    UMDNJ Robert Wood Johnson Medical School, Departments of Medicine and Pharmacology, Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ, USA
    Cancer Chemother Biol Response Modif 20:71-97. 2002
  29. ncbi request reprint A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancy
    Deborah L Toppmeyer
    Departments of Medicine and Pharmacology, Robert Wood Johnson Medical School and The Cancer Institute, University of Medicine and Dentistry, New Brunswick, New Jersey, USA
    Med Sci Monit 9:PI99-104. 2003
    ....
  30. pmc Abiraterone in prostate cancer: a new angle to an old problem
    Mark N Stein
    Cancer Institute of NewJersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA
    Clin Cancer Res 18:1848-54. 2012
    ..These promising results now pose a new angle to an old problem about hormonal therapy and raise new questions about how resistance develops, how to best sequence therapy, and how to optimize combinations with other emerging novel agents...
  31. ncbi request reprint Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies
    Robert S DiPaola
    Department of Medicine, UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
    Med Sci Monit 9:PI5-11. 2003
    ..To investigate a novel schedule of gemcitabine (G), paclitaxel (P), and carboplatin (C), based on preclinical studies demonstrating greater activity and decreased toxicity of administering P prior to C...
  32. ncbi request reprint State-of-the-art treatment of metastatic hormone-refractory prostate cancer
    Susan Goodin
    The Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA
    Oncologist 7:360-70. 2002
    ..Evaluation and incorporation of these agents into existing treatment regimens will guide us in the development of more active regimens in the treatment of HRPC...
  33. ncbi request reprint Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases
    Tianling Chen
    Department of Clinical Pharmacology, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA
    J Clin Pharmacol 42:1228-36. 2002
    ..The antiresorptive effects were evident within 1 day postdose and were maintained over 28 days across all dose levels, supporting monthly dosing with 4 mg zoledronic acid...
  34. doi request reprint Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases
    Patrick J Medina
    College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
    Clin Ther 30:1426-47. 2008
    ....
  35. ncbi request reprint Cancer-treatment-induced bone loss, part 2
    Laura Boehnke Michaud
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Am J Health Syst Pharm 63:534-46. 2006
    ..The pathophysiology, frequency, sequelae, diagnosis, and treatment of cancer-treatment-induced bone loss (CTIBL) are discussed...
  36. ncbi request reprint Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone
    Celeste Lindley
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7360, USA
    Am J Clin Oncol 28:270-6. 2005
    ....
  37. ncbi request reprint Drug-drug interactions in oncology: why are they important and can they be minimized?
    Peter Blower
    Biophar Consulting, Poole House, Great Yeldham, Halstead, Essex CO9 4HP, UK
    Crit Rev Oncol Hematol 55:117-42. 2005
    ..This review considers the basic principles of drug-drug interactions, and presents specific examples that are relevant to oncology...
  38. ncbi request reprint Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate
    Parvesh Kumar
    Department of Radiation Oncology, University of Southern California Keck School of Medicine, Los Angeles, 90033 0804, USA
    J Clin Oncol 22:1909-15. 2004
    ..A phase I trial was conducted to determine the maximally tolerated dose (MTD) of concurrent weekly docetaxel and three-dimensional conformal radiation therapy (3-D CRT) in unfavorable localized adenocarcinoma of the prostate...
  39. ncbi request reprint Conceptualization of disease timeline predicts posttreatment distress in breast cancer patients
    Carolyn Rabin
    Department of Psychiatry and Human Behavior, Brown Medical School and The Miriam Hospital, Providence, RI 02903, USA
    Health Psychol 23:407-12. 2004
    ..The way patients conceptualize their illness appears to be more influential in determining levels of posttreatment distress than objective indicators of the likelihood of recurrence...
  40. ncbi request reprint Cancer-treatment-induced bone loss, part 1
    Laura Boehnke Michaud
    The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Am J Health Syst Pharm 63:419-30. 2006
    ..The pathophysiology, frequency, sequelae, diagnosis, and treatment of cancer-treatment-induced bone loss (CTIBL) are discussed...